Information  X 
Enter a valid email address

Qiagen N.V. (0H1Z)

  Print      Mail a friend       Annual reports

Monday 09 August, 2010

Qiagen N.V.

QIAGEN Reports Solid Second Quarter 2010 Results




Qiagen N.V. / QIAGEN Reports Solid Second Quarter 2010 Results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

  * 11% Revenue growth at constant exchange rates
  * 10% Organic growth excluding H1N1 related effects
  * 25% Net income growth
  * $0.22 Adjusted EPS

Venlo, The Netherlands, August 9, 2010 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt,
Prime Standard: QIA) today announced the results of operations for the second
quarter and the six-month period ended June 30, 2010.

The  reported  net  sales  for  the  second  quarter 2010 were in line with, and
adjusted  earnings per share  were at the  high end of,  the Company's quarterly
expectations as provided on May 4, 2010.
Second Quarter 2010 Results

+----------------------------------------------------------------------------+
| QIAGEN's Second Quarter 2010                                               |
+----------------------------------------------------------------------------+
| in US$ millions, except per share information   Q2 2010   Q2 2009   Growth |
+----------------------------------------------------------------------------+
|                                                                            |
|                                                                            |
| Net sales                                         262.7     240.2       9% |
|                                                                            |
| Net sales at constant exchange rates              265.9     240.2      11% |
|                                                                            |
| Net income                                         38.5      30.9      25% |
|                                                                            |
| Net income, adjusted                               52.5      48.3       9% |
|                                                                            |
| EPS, adjusted( )(US$)                              0.22      0.24          |
|                                                                            |
|                                                                            |
+----------------------------------------------------------------------------+
For information on the adjusted figures, please refer to the reconciliation
table accompanying this release.

The  Company reported that  consolidated net sales  for its second quarter 2010
increased 9% to $262.7 million from $240.2 million in the same quarter of 2009.
Excluding the unfavorable impact from foreign currency exchange rates, net sales
for  the second  quarter 2010 would  have increased  11% from the second quarter
2009. Reported  operating income for  the quarter decreased  9% to $42.8 million
from  $46.9 million in the same quarter  of 2009, and net income for the quarter
increased  25% to $38.5 million from $30.9 million in the same quarter of 2009.
Diluted  earnings per share for  the second quarter increased  to $0.16 in 2010
(based   on   241.6 million   weighted  average  shares  and  share  equivalents
outstanding)  from $0.15 in 2009 (based on 203.8 million weighted average shares
and share equivalents outstanding).

Second  quarter adjusted operating income increased 2% to $73.1 million in 2010
from  $71.8  million  in  2009, and  second  quarter  2010 adjusted  net  income
increased  9% to  $52.5  million  from  $48.3  million in 2009. Adjusted diluted
earnings  per share decreased to $0.22 in 2010 from $0.24 in 2009. These figures
are  adjusted for  business integration,  acquisition related  and restructuring
costs,  a  one-time  tax  benefit,  purchased intangibles amortization and share
based compensation.

Six-Month Period 2010 Results

For  the six-month period ended June 30, 2010, net sales increased 14% to $527.1
million  compared to $461.1 million in  the respective period of 2009. Operating
income  as reported for the six months ended June 30, 2010 increased 4% to $87.5
million  from $83.9  million for  the same  period in 2009. Net income increased
29% to  $71.5 million from $55.6 million in 2009, and diluted earnings per share
increased to $0.30 in 2010 from $0.27 in 2009.

On  an  adjusted  basis,  operating  income  for the six-month period ended June
30, 2010 increased  12% to $146.7 million in  2010 from $130.9 million in 2009,
and  adjusted net  income increased  15% to $101.9  million from  $88.5 million.
Adjusted  diluted  earnings  per  share  in  the six months ended June 30, 2010
decreased to $0.42 per share from $0.44 per share in the same period of 2009.

QIAGEN's second quarter and six-month period 2010 results include the results of
operations from the Company's recent acquisitions, the most significant of which
were SABiosciences Corporation, acquired in December 2009 and DxS Ltd., acquired
in  September 2009. Reconciliations of reported results determined in accordance
with  generally accepted  accounting principles  (GAAP) to  adjusted results are
included in the tables accompanying this release.

"QIAGEN  experienced a  successful second  quarter," said  Peer Schatz, QIAGEN's
Chief   Executive  Officer.  "We  met  our  quarterly  revenue  expectations  as
communicated  in our previous quarterly conference call  and came in on the high
end  of  our  adjusted  EPS  expectations.  Our markets remain stable across our
customer segments and show promising growth opportunities.

"We  achieved  a  substantial  increase  in  product  sales  to our customers in
molecular  diagnostics,  applied  markets,  the  pharmaceutical  industry and in
academia  and remain very well prepared  to exploit further growth opportunities
in our target markets.

"Molecular   diagnostics   remains   our  strongest  revenue  driver  even  when
considering the impacts related to swine flu testing in 2009. The market for our
profiling assays and solutions remains very solid. The market for our prevention
assays  (primarily HPV screening), continues to benefit from our market adoption
initiatives  in the  United States  despite what  is believed  to be a temporary
extension  of doctor visit intervals. Anticipated future healthcare policies and
reimbursement  schemes  world-wide  promise  a  healthy  outlook for this market
segment.  The applied testing  markets show excellent  growth opportunities. Our
recent  addition of more than 70 new food safety tests to our assay technologies
portfolio and the addition of a portfolio of forensic assays position QIAGEN for
further   strong   growth   in  the  applied  testing  customer  class.  In  the
pharmaceutical  industry we observed  a continuing trend  to focus on our sample
and  assay solutions that enable  molecular selection, guidance, progression and
recurrence during the drug development process. With our portfolio of sample and
assay technologies and our broad portfolio of instrument platforms we believe we
are  well  positioned  to  address  the  needs  coming with molecular based drug
development.  In addition we  recently launched our  new SABiosciences portfolio
through  our QIAGEN sales channels, thereby enabling pharmaceutical and academic
partners to advance biomarker discovery and research.

"We feel very well prepared to take advantage of the growth opportunities in our
target markets and are on track to achieve our annual targets."

"We  are pleased with our financial performance in this second quarter of 2010.
Reported  revenues met, and adjusted earnings per share were at the high end of,
our  expectations  for  the  second  quarter  of  2010 as set in our most recent
quarterly  conference call  in early  May," said  Roland Sackers, QIAGEN's Chief
Financial  Officer. "Revenue  growth for  the second  quarter was  9% (11% under
constant  exchange rates).  Organic growth  excluding H1N1  related revenues was
strong at 10% and we realized a positive contribution from acquisitions of 7%.

"Our  consumable portfolio represented approximately  85% of our total net sales
and  contributed approximately  10% growth at  constant exchange rates. QIAGEN's
instrumentation  products represented  approximately 14% of  our total net sales
and  grew with approximately 10% at constant exchange rates. The largest revenue
share  we  recorded  in  the  second  quarter  2010 was in sales to customers in
molecular diagnostics (approximately 47% of total revenues) followed by sales to
customers   in   academia   (approximately   24% of   total  revenues),  in  the
pharmaceutical  industry (approximately  22% of total  revenues) and  in applied
testing markets (approximately 7% of total revenues).

"We  are reiterating  our guidance  for the  fiscal year  2010. Based on foreign
currency  exchange rates as of  January 31, 2010, this guidance targets revenues
between  $1,120  and  $1,170  million  and  adjusted  diluted earnings per share
between  $0.90  and  $0.96.  The  guidance  on  EPS, adjusted does not include a
negative  contribution for 2010 of approximately US$0.01 from the acquisition of
all  rights  to  a  portfolio  of  molecular  food safety tests developed by the
Institute for Product Quality (ifp) in May 2010."

QIAGEN - Sample and Assay Technologies Highlights

  * QIAGEN extended its development agreement with Genome Diagnostics targeting
    the development and commercialization of a series of new assays to detect
    genetic variations in the so called Human Leukocyte Antigen (HLA) complex.
    These assays are increasingly used in personalized healthcare (PHC). The
    assays will include tests based on QIAGEN's proprietary "Pyrosequencing"
    technology which enables fast, cost effective and accurate analysis of HLA
    sequences, and allows for direct detection of previously unknown
    polymorphisms. QIAGEN believes that this collaboration will further expand
    the Company's testing portfolio for the early detection of diseases and
    individualized treatment of patients - thereby strengthening QIAGEN's
    molecular diagnostics offering for applications in prevention and
    personalized healthcare (PHC).

  * QIAGEN acquired all rights to a portfolio of 70 molecular food safety tests
    developed by the Institute for Product Quality (ifp). The tests are based on
    real-time PCR (Polymerase Chain Reaction) technology and cover a broad range
    of molecular targets including genetic, bacterial, viral and other
    contaminants of food products. The tests can be fully automated using
    QIAGEN's instrument platforms such as the QIAsymphony and the Rotor-Gene Q.
    The transaction enables QIAGEN to offer complete solutions for all major
    applications in the food safety testing segment, covering entire workflows
    from the processing of primary samples to the final testing result. The
    first test kits are expected to be available through QIAGEN in the fourth
    quarter of 2010.

  * QIAGEN added a range of Human Identity (HID) PCR assays for human identity
    testing applications in forensics to its assay technologies portfolio
    through the acquisition of various assets from a leading forensics assay
    supplier in Europe. Our new human ID assay portfolio includes IP, know-how
    and co-exclusive rights to innovative software suites for analysis of STR
    genotyping data. The assay portfolio features comprehensive coverage of
    international STR (short tandem repeat) marker standards, including the new
    European Standard Set (ESS) as defined by the Council of the European Union
    in the effort to harmonize Europe's national DNA databases.

  * QIAGEN announced a donation of one million HPV tests to low-income countries
    over five years, following the April 2009 publication of study results in
    The New England Journal of Medicine. The control group in the study had no
    screening, which is the standard of care in many parts of India. From the
    company's "one million test" donation program, QIAGEN allocated first
    grants, including a donation of approximately 26,000 human papillomavirus
    (HPV) tests to the Nargis Dutt Memorial Cancer Hospital in India for
    cervical cancer screening.

  * QIAGEN completed the European certification of its careHPV(TM) Test to bring
    human papillomavirus (HPV) testing to public-health programs in
    low-resource, developing countries. The CE conformity marking ("Conformité
    Européenne") certifies that the careHPV Test has met European Union consumer
    safety and health requirements, allowing the test to be distributed in
    developing countries that recognize the CE mark.

  * QIAGEN launched 19 new products/product groups in the area of Sample & Assay
    Technologies including the SABiosciences portfolio for gene and pathway
    analysis as well as a number of molecular diagnostic assays including a
    CE-labeled artus real time PCR assay for the detection of the Herpes-Simplex
    virus and the EASYartus PCR assay for the detection of the Cytomegalus
    virus.


Conference Call and Webcast Details

Detailed  information  on  QIAGEN's  business  and financial performance will be
presented  during  its  conference  call  on  August  10, 2010 at 9:30am ET. The
corresponding  presentation  slides  will  be  available  for  download  on  the
Company's  website  at  www.qiagen.com/goto/ConferenceCall.  A  webcast  of  the
conference call will also be available at www.qiagen.com/goto/ConferenceCall.

Use of Adjusted Results

QIAGEN  has regularly reported adjusted results  to give additional insight into
its financial performance as well as considered results on a constant currencies
basis. Adjusted results should be considered in addition to the reported results
prepared in accordance with generally accepted accounting principles, but should
not  be considered as a substitute. The Company believes certain items should be
excluded  from  adjusted  results  when  they  are  outside  of its ongoing core
operations,   vary   significantly   from   period  to  period,  or  affect  the
comparability  of  results  with  the  Company's  competitors  and its own prior
periods. Reconciliations of reported results to adjusted results are included in
the tables accompanying this release.

About QIAGEN

QIAGEN  N.V., a Netherlands  holding company, is  the leading global provider of
sample  and  assay  technologies.  Sample  technologies  are used to isolate and
process  DNA, RNA and proteins from biological  samples such as blood or tissue.
Assay  technologies are used to make these isolated biomolecules visible. QIAGEN
has  developed and markets  more than 500 sample  and assay products  as well as
automated  solutions for such consumables. The  Company provides its products to
molecular  diagnostics  laboratories,  academic  researchers, pharmaceutical and
biotechnology  companies,  and  applied  testing  customers for purposes such as
forensics,  animal or food testing  and pharmaceutical process control. QIAGEN's
assay  technologies include one  of the broadest  panels of molecular diagnostic
tests  available worldwide. This panel includes  the first FDA-approved test for
human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs
more than 3,500 people in over 30 locations worldwide. Further information about
QIAGEN can be found at 

http://www.qiagen.com/.

Certain  of  the  statements  contained  in  this news release may be considered
forward-looking  statements  within  the  meaning  of  Section  27A of  the U.S.
Securities  Act  of  1933, as  amended,  and  Section 21E of the U.S. Securities
Exchange  Act of  1934, as amended.  To the  extent that  any of  the statements
contained  herein relating to QIAGEN's  products, markets, strategy or operating
results,  including  without  limitation  its  expected  operating  results, are
forward-looking,   such   statements  are  based  on  current  expectations  and
assumptions that involve a number of uncertainties and risks. Such uncertainties
and  risks include, but are not limited  to, risks associated with management of
growth   and   international  operations  (including  the  effects  of  currency
fluctuations,  regulatory processes and dependence on logistics), variability of
operating  results  and  allocations  between  business segments, the commercial
development of markets for our products in applied testing, personal healthcare,
clinical  research, proteomics,  women's health/HPV  testing, nucleic acid-based
molecular  diagnostics,  and  genetic  vaccination  and  gene  therapy, changing
relationships  with  customers,  suppliers  and strategic partners, competition,
rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's
products  (including fluctuations due to  general economic conditions, the level
and  timing of customers'  funding, budgets, and  other factors), our ability to
obtain  regulatory approval  of our  infectious disease  panels, difficulties in
successfully  adapting QIAGEN's  products to  integrated solutions and producing
such products, the ability of QIAGEN to identify and develop new products and to
differentiate  and  protect  its  products  from  competitors'  products, market
acceptance of QIAGEN's new products and the integration of acquired technologies
and  businesses. For  further information,  refer to  the discussions in reports
that  QIAGEN has filed with,  or furnished to, the  U.S. Securities and Exchange
Commission (SEC).

                                      ###


                                  QIAGEN N.V.
                  CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                  (unaudited)

                                                         Three months
                                                        ended  u e 30,
(in US$ thousands, except per share data)
                                                     --------------------


                                                        2010       2009
                                                     ---------- ---------
Net sales                                              262,718    240,156

  Cost of sales                                         89,912     80,656
                                                     ---------- ---------
Gross profit                                           172,806    159,500
                                                     ---------- ---------


Operating expenses:

  Research and development                              29,423     24,950

  Sales and marketing                                   66,255     59,039

  General and administrative, integration and other     28,438     24,618

  Acquisition-related intangible amortization            5,840      4,011
                                                     ---------- ---------
Total operating expenses                               129,956    112,618
                                                     ---------- ---------


Income from operations                                  42,850     46,882
                                                     ---------- ---------


Other income (expense):

  Interest income                                        1,501        678

  Interest expense                                     (7,669)    (7,302)

  Other income, net                                      2,858        778
                                                     ---------- ---------
Total other expense                                    (3,310)    (5,846)
                                                     ---------- ---------


Income before provision for income taxes                39,540     41,036

Provision for income taxes                               1,020     10,107
                                                     ---------- ---------
Net income                                              38,520     30,929



  Weighted average number of diluted common shares     241,636    203,785



  Diluted net income per common share                   $ 0.16     $ 0.15



  Diluted net income per common share, adjusted         $ 0.22     $ 0.24



                                  QIAGEN N.V.
                  CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                  (unaudited)

                                                           Six months
                                                         ended  u e 30,
(in US$ thousands, except per share data)
                                                     ----------------------


                                                        2010        2009
                                                     ----------- ----------
Net sales                                               527,082     461,089

  Cost of sales                                         181,064     155,140
                                                     ----------- ----------
Gross profit                                            346,018     305,949
                                                     ----------- ----------


Operating expenses:

  Research and development                               61,021      50,593

  Sales and marketing                                   130,690     115,137

  General and administrative, integration and other      54,778      48,406

  Acquisition-related intangible amortization            11,998       7,902
                                                     ----------- ----------
Total operating expenses                                258,487     222,038
                                                     ----------- ----------


Income from operations                                   87,531      83,911
                                                     ----------- ----------


Other income (expense):

  Interest income                                         2,190       1,863

  Interest expense                                     (13,923)    (14,732)

  Other income, net                                       5,093       2,558
                                                     ----------- ----------
Total other expense                                     (6,640)    (10,311)
                                                     ----------- ----------


Income before provision for income taxes                 80,891      73,600

Provision for income taxes                                9,358      17,987
                                                     ----------- ----------
Net income                                               71,533      55,613



  Weighted average number of diluted common shares      241,780     203,476



  Diluted net income per common share                    $ 0.30      $ 0.27



  Diluted net income per common share, adjusted          $ 0.42      $ 0.44



                                  QIAGEN N.V.
                     CONDENSED CONSOLIDATED BALANCE SHEETS

(in US$ thousands, except par value)                 June 30,      December 31,

                                                       2010            2009
                                                  --------------- --------------
Assets                                              (unaudited)



Current Assets:

  Cash and cash equivalents                              844,209         825,557

  Short-term investments                                  74,000          40,000

  Accounts receivable, net                               189,958         193,737

  Income taxes receivable                                 14,714          12,907

  Inventories, net                                       117,808         130,851

  Prepaid expenses and other                              80,456          96,893

  Deferred income taxes                                   31,605          33,525
                                                  --------------- --------------
        Total current assets                           1,352,750       1,333,470
                                                  --------------- --------------


Long-Term Assets:

  Property, plant and equipment, net                     303,381         317,467

  Goodwill                                             1,316,955       1,337,064

  Intangible assets, net                                 713,664         752,296

  Deferred income taxes                                   29,202          26,387

  Other assets                                            51,833          29,780
                                                  --------------- --------------
        Total long-term assets                         2,415,035       2,462,994
                                                  --------------- --------------

                                                  --------------- --------------
    Total assets                                       3,767,785       3,796,464



Liabilities and Shareholders' Equity



Current Liabilities:

  Accounts payable                                        49,007          43,775

  Accrued and other liabilities                          188,653         248,699

  Income taxes payable                                    13,672          10,727

  Current portion of long-term debt                       50,977          50,000

  Current portion of capital lease obligations             3,346           3,417

  Deferred income taxes                                   16,356          18,912
                                                  --------------- --------------
        Total current liabilities                        322,011         375,530
                                                  --------------- --------------


Long-Term Liabilities:

  Long-term debt, net of current portion                 871,783         870,000

  Capital lease obligations, net of current               24,353          27,554
  portion

  Deferred income taxes                                  201,877         212,690

  Other liabilities                                       13,218          19,521
                                                  --------------- --------------
        Total long-term liabilities                    1,111,231       1,129,765
                                                  --------------- --------------


Shareholders' Equity:

  Common shares, EUR .01 par value:

    Authorized--410,000 shares

    Issued and outstanding--232,703 shares

      in 2010 and 232,074 shares in 2009                   2,720           2,711

    Additional paid-in-capital                         1,637,656       1,622,733

    Retained earnings                                    687,112         615,579

    Accumulated other comprehensive income                 7,055          50,146
                                                  --------------- --------------
        Total shareholders' equity                     2,334,543       2,291,169
                                                  --------------- --------------

                                                  --------------- --------------
    Total liabilities and shareholders' equity         3,767,785       3,796,464





                                  QIAGEN N.V.
                 RECONCILIATION OF REPORTED TO ADJUSTED FIGURES
                                  (unaudited)

                        Three months ended June 30, 2010

                       (in US$ millions, except EPS data)



                             Gross   Operating  Pre-tax  Income    Net   Diluted
                 Net Sales  Profit     Income    Income    Tax   Income   EPS*
                ----------------------------------------------------------------

Reported results     262.7     172.8       42.8     39.5   (1.0)    38.5  $ 0.16

Adjustments:

  Business
  integration,
  acquisition
  related and
  restructuring
  costs and tax
  benefit from
  restructuring          -         -        5.5      5.5   (7.7)   (2.2)  (0.01)

  Purchased
  intangibles
  amortization           -      15.3       21.1     21.1   (7.5)    13.6    0.06

  Share-based
  compensation           -       0.3        3.7      3.7   (1.1)     2.6    0.01
                ----------------------------------------------------------------
  Total
  adjustments            -      15.6       30.3     30.3  (16.3)    14.0    0.06
                ----------------------------------------------------------------

Adjusted results     262.7     188.4       73.1     69.8  (17.3)    52.5  $ 0.22



*  Using 241.6 M diluted shares





                        Three months ended June 30, 2009

                       (in US$ millions, except EPS data)



                             Gross   Operating  Pre-tax  Income    Net   Diluted
                 Net Sales  Profit     Income    Income    Tax   Income   EPS*
                ----------------------------------------------------------------

Reported results     240.2     159.5       46.9     41.0  (10.1)    30.9  $ 0.15

Adjustments:

  Business
  integration,
  acquisition
  related and
  restructuring
  costs                  -       0.3        4.9      4.9   (1.6)     3.3    0.02

  Purchased
  intangibles
  amortization           -      13.2       17.2     17.2   (6.0)    11.2    0.06

  Share-based
  compensation           -       0.2        2.8      2.8   (0.8)     2.0    0.01

  Acquisition
  related
  write-off of
  prepaid
  expenses               -         -          -      1.2   (0.3)     0.9       -
                ----------------------------------------------------------------
  Total                                    24.9
  adjustments            -      13.7                26.1   (8.7)    17.4    0.09
                ----------------------------------------------------------------
Adjusted results     240.2     173.2       71.8     67.1  (18.8)    48.3  $ 0.24



*  Using 203.8 M diluted shares


                                  QIAGEN N.V.
                 RECONCILIATION OF REPORTED TO ADJUSTED FIGURES
                                  (unaudited)

                         Six months ended June 30, 2010

                       (in US$ millions, except EPS data)



                  Net    Gross  Operating  Pre-tax               Net     Diluted
                 Sales  Profit    Income    Income  Income Tax  Income    EPS*
                ----------------------------------------------------------------
                                                                              $
Reported results  527.1   346.0       87.5     80.9       (9.4)   71.5      0.30

Adjustments:

  Business
  integration,
  acquisition
  related and
  restructuring
  costs and tax
  benefit from
  restructuring      -      0.8       10.5     10.5      (12.0)  (1.5)    (0.01)

  Purchased
  intangible
  amortization       -     30.4       42.4     42.4      (15.0)   27.4      0.11

  Share-based
  compensation       -      0.4        6.3      6.3       (1.8)    4.5      0.02
                ----------------------------------------------------------------
  Total
  adjustments        -     31.6       59.2     59.2      (28.8)   30.4      0.12
                ----------------------------------------------------------------
                                                                              $
Adjusted results  527.1   377.6      146.7    140.1      (38.2)  101.9      0.42



*  Using 241.8 M diluted shares





                         Six months ended June 30, 2009

                       (in US$ millions, except EPS data)



                  Net    Gross  Operating  Pre-tax               Net     Diluted
                 Sales  Profit    Income    Income  Income Tax  Income    EPS*
                ----------------------------------------------------------------
                                                                              $
Reported Results  461.1   305.9       83.9     73.6      (18.0)   55.6      0.27

Adjustments:

  Business
  integration,
  acquisition
  related and
  restructuring
  costs              -      0.5        7.9      7.9       (2.5)    5.4      0.03

  Purchased
  intangible
  amortization       -     26.2       34.1     34.1      (11.9)   22.2      0.11

  Share-based
  compensation       -      0.5        5.0      5.0       (1.5)    3.5      0.02

  Acquisition
  related
  write-off of
  prepaid
  expenses and
  other asset
  impairment         -       -          -       2.7       (0.9)    1.8      0.01
                ----------------------------------------------------------------
  Total
  adjustments        -     27.2       47.0     49.7      (16.8)   32.9      0.17
                ----------------------------------------------------------------
Adjusted results                                                              $
                  461.1   333.1      130.9    123.3      (34.8)   88.5      0.44



*  Using 203.5 M diluted shares


Contacts:

 Dr. Solveigh Mähler                    Dr. Thomas Theuringer
 Director Investor Relations            Director Public Relations
 QIAGEN N.V.                            QIAGEN N.V.
 +49 2103 29 11710                      +49 2103 29 11826
 e-mail:[email protected]     e-mail:[email protected]

 Albert F. Fleury
 Director Corporate Finance
 and Investor Relations North America
 QIAGEN N.V.
 +1 301 944 7028
 e-mail:[email protected]iagen.com




[HUG#1436757]



 --- End of Message --- 

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands


Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse;





This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
All reproduction for further distribution is prohibited.
    
Source: Qiagen N.V. via Thomson Reuters ONE
  



                                                                                                                                                   

a d v e r t i s e m e n t